MedTrace Logo

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

NCT01885260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2016-07-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin

Conditions

Interventions

DRUG

ISIS-GCGRRx - Dose Level 1

3 doses on alternate days during the first week and then once weekly for 12 weeks

DRUG

ISIS-GCGRRx - Dose Level 2

3 doses on alternate days during the first week and then once weekly for 12 weeks

DRUG

Placebo

3 doses on alternate days during the first week and then once weekly for 12 weeks

Sponsors & Collaborators

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-05-31
Completion
2014-11-30

Countries

  • United States
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885260 on ClinicalTrials.gov